Vertex Pharmaceuticals Inc. — Q1 2024 Form 10-Q
Reporting period: Unaudited three months ended March 31, 2024; comparisons are with Q1 2023 unless noted. Vertex operates in one pharmaceutical segment. Q1 product revenue was from cystic fibrosis (CF) products.
Financial results and position
| Metric | Q1 2024 | Q1 2023 / comparator | Change |
|---|---|---|---|
| Net product revenue | $2,690.6 million | $2,374.8 million | +13% |
| Income from operations | $1,139.5 million | $779.0 million | +46% |
| Net income | $1,099.6 million | $699.8 million | +57% |
| Diluted EPS | $4.21 | $2.69 | Increased |
| Operating cash flow | $1,306.6 million | $899.9 million | Increased |
- Revenue mix: TRIKAFTA/KAFTRIO generated $2,483.6 million, up 18%; other CF products generated $207.0 million, down 26%. U.S. revenue grew 8% to $1,519.9 million; ex-U.S. revenue grew 21% to $1,170.7 million.
- Margins and expenses: Cost of sales was 13% of revenue versus 11%, primarily reflecting CASGEVY-related costs. Operating margin was approximately 42.4%, compared with 32.8% (calculated from reported revenue and operating income). R&D was $789.1 million, up 6%; SG&A was $342.7 million, up 42%; acquired in-process R&D was $76.8 million versus $347.1 million.
- Cash and liquidity: Cash, cash equivalents and marketable securities totaled $14.55 billion at March 31, up from $13.72 billion at year-end. Working capital was $9.49 billion, down from $10.60 billion, mainly due to purchases of long-term marketable securities. Investing cash outflow was $2.14 billion, primarily reflecting net purchases of debt securities; financing outflow was $357.5 million.
- Debt and obligations: The balance sheet reports no funded borrowings. Vertex’s $500 million revolving credit facility was undrawn, and the company was in covenant compliance. Long-term finance and operating lease liabilities were $361.5 million and $359.8 million, respectively. The filing states cash and current marketable securities plus operating cash flows should fund operations for at least 12 months.
Material changes and unusual items
- Revenue growth was driven by TRIKAFTA/KAFTRIO uptake, particularly in ex-U.S. markets, reimbursement and label expansions, and U.S. use among children ages 2–5. Revenue from other CF products declined primarily as patients switched to TRIKAFTA/KAFTRIO.
- Lower acquired in-process R&D compared with Q1 2023 partly offset higher R&D and SG&A. Q1 2024 acquired in-process R&D primarily included a $75 million Entrada milestone; Q1 2023 included $225.1 million paid to Entrada and $100 million to CRISPR.
- Net income benefited from a lower effective tax rate of 14.0%, versus 21.5%, and higher interest income ($181.2 million versus $122.6 million). Other non-operating results shifted to a $31.2 million expense from $1.3 million of income, primarily reflecting fair-value changes in strategic equity investments.
- In April 2024, Vertex agreed to acquire Alpine Immune Sciences for approximately $4.9 billion cash, intended to be funded from cash and cash equivalents. Closing was expected in Q2 2024, subject to customary conditions; it is a subsequent event, not a Q1 completed transaction.
- Vertex repurchased $140.4 million of shares in Q1 and had approximately $2.4 billion remaining under its authorization. A $24.3 million reduction in the carrying value of an equity investment without a readily determinable fair value was recorded during the quarter.
Outlook, management commentary and risks
- No specific full-year revenue or earnings guidance is provided in the supplied filing text. Management expects continued CF growth from market uptake, reimbursement and label expansions, and is preparing potential launches in CF and acute pain.
- Vertex submitted U.S. and European marketing applications for vanzacaftor/tezacaftor/deutivacaftor for CF patients age 6 and older. It expected additional global submissions in 2024. For suzetrigine in acute pain, the company expected to complete its U.S. NDA submission in Q2 2024.
- CASGEVY had approvals in the U.S., EU, U.K., Saudi Arabia and Bahrain for eligible patients with sickle cell disease or transfusion-dependent beta thalassemia. Vertex reported more than 25 activated treatment centers globally and ongoing work to secure reimbursement and access.
- Pipeline milestones include planned Phase 3 development of suzetrigine for diabetic peripheral neuropathy in the second half of 2024; anticipated VX-522 CF trial data in late 2024 or early 2025; and plans to start povetacicept Phase 3 development for IgA nephropathy in the second half of 2024, contingent on the Alpine acquisition closing.
- Key risks include clinical and regulatory uncertainty, obtaining and maintaining reimbursement, manufacturing and supply-chain constraints (including potential trade restrictions), and completing and integrating the Alpine acquisition. The filing reports no material legal proceedings and no material contingent liabilities accrued apart from contingent consideration. Net unrecognized tax benefits were $301.6 million; Vertex expects to pursue U.S.-U.K. treaty procedures following a U.K. tax settlement.
Important facts for investors to verify
- Whether CF product growth and the shift toward TRIKAFTA/KAFTRIO continue, and how much CASGEVY contributes commercially.
- Regulatory review timing and outcomes for the vanzacaftor triple and suzetrigine, and progress against the stated pipeline timelines.
- Completion, cash funding and integration risks of the approximately $4.9 billion Alpine acquisition.
- Changes in cost of sales, R&D, launch-related SG&A, and the effective tax rate, including investment fair-value volatility.
- How cash, marketable securities, share repurchases and potential milestone or royalty obligations affect liquidity after the acquisition.